InMed Pharmaceuticals Inc. (INM) vs Redhill Biopharma Ltd. (RDHL)
- InMed Pharmaceuticals Inc. INM 1.32 −0.75%
- Redhill Biopharma Ltd. RDHL 0.48 −4.00%
InMed Pharmaceuticals Inc. and Redhill Biopharma Ltd. are both Drug Manufacturers Specialty & Generic companies. InMed Pharmaceuticals Inc. is the larger, with a market value of $7.3M against $4.4M — 1.6× the size. InMed Pharmaceuticals Inc. grew revenue faster over the last twelve months: 19.4% against −61.9%. Redhill Biopharma Ltd. has the higher net margin (25.2% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, InMed Pharmaceuticals Inc. leads on 6 and Redhill Biopharma Ltd. on 6.
Valuation
| Metric | INM | RDHL | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 19.25 |
| P/S | 0.95 | 0.00 | 2.11 |
| P/B | 5.11 | n/m | 1.78 |
| Price to free cash flow | n/m | n/m | 16.14 |
| EV/EBITDA | n/m | n/m | 12.58 |
| EV/Sales | 0.58 | 6.43 | 2.73 |
| Earnings yield | (228.36%) | (127,222.23%) | (4.38%) |
| Free cash flow yield | (158.00%) | (246,986.61%) | 0.00% |
Profitability
| Metric | INM | RDHL | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 26.27% | 35.16% | 53.94% |
| Operating margin | 0.00% | 0.00% | 0.00% |
| Net margin | 0.00% | 25.20% | 0.00% |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | (179.09%) | 0.00% | (0.40%) |
| Return on assets | (139.63%) | 0.00% | (3.32%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack